<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363400</url>
  </required_header>
  <id_info>
    <org_study_id>T1313</org_study_id>
    <nct_id>NCT02363400</nct_id>
  </id_info>
  <brief_title>A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA</brief_title>
  <official_title>Phase III Randomized Trial of Immediate Adjuvant Chemotherapy or Delayed Salvage Chemotherapy in Nasopharyngeal Carcinoma Patients With Post-radiation Detectable Plasma EBV DNA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nasopharyngeal carcinoma (NPC) is a geographically endemic, Epstein-Barr virus&#xD;
      (EBV)-associated carcinoma of epidermoid origin. It occurs most commonly in Southern China&#xD;
      and Southeast Asia. The NPC cells are poorly differentiated or undifferentiated with a high&#xD;
      incidence of lymphatic and hematological dissemination. Because of the inherent anatomic&#xD;
      constraints and a high degree of radiosensitivity, radiotherapy (RT) has been the primary&#xD;
      treatment for NPC patients.&#xD;
&#xD;
      NPC is also a chemosensitive tumor. Various modes of combined chemoradiotherapy have been&#xD;
      used to treat NPC patients with advanced-stage diseases during recent 20 years. However,&#xD;
      treatment outcome for locoregionally advanced NPC is still unsatisfactory.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current NCCN guidelines recommend that CCRT + adjuvant chemotherapy for advanced (stage&#xD;
      III-IV) NPC, originated from the results of the Intergroup study [69]. However, all&#xD;
      meta-analysis reported no any benefit in using adjuvant chemotherapy for NPC patients&#xD;
      [82-85]. These contradictions puzzle most oncologists for decades. In our opinion, routine&#xD;
      delivery of post-radiation adjuvant chemotherapy after RT±induction/concurrent chemotherapy&#xD;
      for &quot;all&quot; advanced-stage NPC patients should be re-considered. The major goal of adjuvant&#xD;
      chemotherapy in NPC is to reduce the occurrences of distant failure. But, not all advanced&#xD;
      NPC patients need adjuvant chemotherapy. In our previous phase III study, only 19.1% (27/141)&#xD;
      NPC patients with 1988 AJCC stage III-IV disease developed distant failure after CCRT . In&#xD;
      another study of 210 NPC patients with 1997 AJCC stage IIB-IVB treated by induction&#xD;
      chemotherapy + RT, 55 patients (26.2%) suffered from subsequent distant metastasis [67]. We&#xD;
      should remember that unnecessary adjuvant therapy is frequently used. For example, if the&#xD;
      target patients have as high as 50% subsequent distant failure rate, and the adjuvant therapy&#xD;
      protocol has a 50% control rate for the subclinical disease. When we treat all target&#xD;
      patients, only 25% patients benefit from the adjuvant therapy because of unnecessary&#xD;
      treatment in 50% and ineffective treatment in another 25% patients. Thus, adjuvant therapy&#xD;
      should be designed for &quot;selected&quot; patients. For NPC patients, pEBV DNA-guided adjuvant&#xD;
      therapy trial is very reasonable. We plan to prove that adjuvant chemotherapy is beneficial&#xD;
      for post-radiation detectable pEBV DNA patients in this prospective multi-center trial. We&#xD;
      will conduct another trial to investigate (compare) which adjuvant chemotherapy regimen is&#xD;
      the best one in the future.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival and relapse rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile and tolerance, according to CTCAE 4.1</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predicting value of plasma EBV DNA</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">147</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Adjuvant Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEP followed by oral Tegafur-uracil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>closely followed with frequency similar to the experiemental arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEP</intervention_name>
    <description>Adjuvant Chemotherapy</description>
    <arm_group_label>Adjuvant Chemotherapy</arm_group_label>
    <other_name>epirubicin</other_name>
    <other_name>cisplatin</other_name>
    <other_name>oral Tegafur-uracil</other_name>
    <other_name>mitomycin-C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.Histological proven NPC.&#xD;
&#xD;
        2.2010 AJCC stage II-IVB.&#xD;
&#xD;
        3.Age ≧ 20 years old.&#xD;
&#xD;
        4.Performance status of ECOG ≦ 2.&#xD;
&#xD;
        5.Finished RT ≧ 66 Gy (± induction and/or concurrent chemotherapy).&#xD;
&#xD;
        6.pEBV DNA &gt; 0 copy/ml at 1±1 week post-RT.&#xD;
&#xD;
        7.Re-staging work-ups at 10±2 weeks post-RT showing no active lesions.&#xD;
&#xD;
        8.Adequate liver, renal, and bone marrow function 4 weeks before randomization.&#xD;
&#xD;
        9.Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pathologically-proven the presence of locoregional disease and/or distant metastasis.&#xD;
&#xD;
          2. Unequivocally-shown active NPC (locoregional/distant) by imaging studies.&#xD;
&#xD;
          3. Inadequate RT.&#xD;
&#xD;
          4. Received any post-RT adjuvant chemotherapy.&#xD;
&#xD;
          5. pEBV DNA = 0 copy/ml at 1±1 week post-RT.&#xD;
&#xD;
          6. Previous delivery of cisplatin dose &gt; 600 mg/m2.&#xD;
&#xD;
          7. Previous delivery of epirubicin &gt; 360 mg/m2.&#xD;
&#xD;
          8. History of a malignancy except those treated with curative intent for skin cancer&#xD;
             (other than melanoma), in situ cervical cancer, ductal carcinoma in situ (DCIS) of&#xD;
             breast.&#xD;
&#xD;
          9. Severe cardiopulmonary diseases (unstable angina and/or congestive heart failure or&#xD;
             peripheral vascular disease requiring hospitalization within the last 12 months;&#xD;
             chronic obstructive pulmonary disease exacerbation other respiratory illness requiring&#xD;
             hospitalization) or clinically significant psychiatric disorders.&#xD;
&#xD;
         10. Female patients who are pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Ching Lin, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>December 4, 2014</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2015</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma (NPC)</keyword>
  <keyword>Epstein-Barr virus (EBV)</keyword>
  <keyword>radiotherapy (RT)</keyword>
  <keyword>Plasma EBV DNA(pEBV DNA)</keyword>
  <keyword>Adjuvant Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

